


Available online at www.sciencedirect.com

ScienceDirect

journal homepage: <http://www.journals.elsevier.com/international-journal-of-epilepsy>

Original Article

Quality of life predictors in patients with epilepsy and cognitive disabilities



Ekaterina Ivanova Viteva*

Department of Neurology, University of Medicine, Plovdiv 42, Bulgaria

ARTICLE INFO

Article history:

Received 18 November 2013

Accepted 29 June 2014

Available online 17 July 2014

Keywords:

Stigma

Depression

Anxiety

Seizure frequency

Severity

ABSTRACT

Purpose: We aimed to assess the QOL and its predictors in Bulgarian patients with refractory epilepsy (RE) and cognitive problems.

Methods: We conducted a study based on questionnaires designed for people with intellectual disability (the stigma scale, the Glasgow Depression Scale, the Glasgow Anxiety Scale, the Glasgow Epilepsy Outcome Scale – GEOS-35) and a purposeful interview on clinical and social factors of 64 patients (50% men) with RE and cognitive problems.

Results: The mean total score of the GEOS-35 was 76 ± 2.34 (an indicator of low QOL). On univariate analysis, the GEOS-35 total score was associated with seizure frequency and severity, stigma, depression, and anxiety. On multivariate regression analysis predictors of the GEOS-35 total score were anxiety, seizure severity, and stigma $P < 0.001$ ($F = 14.66$). Regarding the GEOS-35 subscales, on multivariate regression analysis, we found that 1. Seizure severity, seizure type, and anxiety were predictors of “concerns about seizures” $P < 0.001$ ($F = 8.99$); 2. Anxiety was the only predictor of “concerns about treatment” $P < 0.001$ ($F = 7.98$); 3. Anxiety and seizure severity were predictors of “concerns about caring” $P < 0.001$ ($F = 12.12$); and 4. Seizure severity and stigma were predictors of “concerns about social impact” $P < 0.001$ ($F = 18.31$).

Conclusions: We have affirmed the low QOL in patients with RE and cognitive problems and its clinical and social determinants. The results from our study prove the necessity of a multidisciplinary approach for quality of life improvement in these patients.

Copyright © 2014, Indian Epilepsy Society. Published by Reed Elsevier India Pvt. Ltd. All rights reserved.

1. Introduction

Quality of life assessment in patients with refractory epilepsy is a result of the refraction of the particular clinical and psycho-social features of the disease through the prism of individual and subjective concepts, relations, and experience.

Generally, epilepsy has a great influence on all aspects of quality of life (physical, mental and social health), which is exercised directly – by affecting the physical and mental health, and indirectly – by introducing limitations and decreasing the opportunities for taking part in quality of life improving activities. Epilepsy is more prevalent in people with intellectual disabilities than the general population.^{1,2}

* Tel.: +359 887752235.

E-mail address: eiviteva@abv.bg
<http://dx.doi.org/10.1016/j.ijep.2014.06.001>

2213-6320/Copyright © 2014, Indian Epilepsy Society. Published by Reed Elsevier India Pvt. Ltd. All rights reserved.

Previous studies have paid scant attention to the quality of life of people with epilepsy and cognitive problems.² Knowledge about the specific needs of these patients and the concerns of their families, which could improve skills training, social integration, and quality of life, is insufficient. No study of quality of life (QOL) and its predictors in patients with refractory epilepsy (RE) and cognitive problems has been performed in Bulgaria.

1.1. Purpose of the study

Assessment of the quality of life and its predictors in Bulgarian patients with cognitive problems and refractory epilepsy.

2. Patients and methods

The study was performed with the participation of a representative extract of 246 patients with epilepsy who attended the Clinic of Neurology at the University Hospital in Plovdiv, Bulgaria for a regular examination or in cases of unsatisfactory seizure control or adverse events from treatment.

All study procedures were performed after the approval of the Local Ethics Commission at the University of Medicine, Plovdiv. Every patient was introduced to the study design and an informed consent form was signed by the patient or the patient's guardian/caregiver before participation in the study procedures.

The study included 64 patients with RE and cognitive problems who fulfilled the inclusion criteria. We accepted epilepsy as refractory in cases in which adequate seizure control with at least two potentially effective anti-epileptic drugs prescribed as mono- or polytherapy in maximal tolerated doses had not been achieved for a period of one year or three times longer period than the longest interictal period in the last year. We used the following inclusion criteria: a signed informed consent form; age between 18 and 65 years; a diagnosis of RE; cognitive impairment based on the Evaluation rapide des fonctions cognitives (ERFC)³ with a score <47 in patients up to 60 years of age and primary education, or <46 in patients between 60 and 65 years of age and less than a primary education or illiteracy; lack of progressive somatic or neurological disease; lack of a simple or complex partial seizure in the last 4 h; and lack of generalised tonic-clonic seizures in the last 24 h. We defined mild cognitive impairment as cases with an ERFC score of 36–46/47, moderate cognitive impairment as cases with a score of 17–35, and severe cognitive impairment as cases with a score of less than 17.

We investigated the correlations between depression, anxiety, demographics (age and gender), degree of cognitive impairment, clinical findings (seizure frequency and severity, seizure type, type of epilepsy, aetiology of epilepsy, focal neurological deficit, and prescribed treatment), stigmatisation, social status (marital status, education, and occupation), and the quality of life. The data were collected by a trained health professional by means of a purposeful interview and examination of the patients' medical documentation.

With the help of their principal caregivers (carers who had participated in care decisions for at least the preceding three months) 56 patients with mild to moderate intellectual

disability completed the Glasgow Depression Scale for people with a Learning Disability (GDS-LD),⁴ the Glasgow Anxiety Scale for people with Intellectual Disability (GAS-ID),⁵ and the stigma scale.⁶ A good reliability and high internal consistency was proven for all of these scales.^{4–6}

The Liverpool Seizure Severity Scale (LSSS)⁷ was fulfilled by 59 participants who had a seizure in the previous month. In cases with severe cognitive impairment, caregivers completed the LSSS and the carer supplement of the GDS-LD (GDS-CD).⁴

The Glasgow Epilepsy Outcome Scale (GEOS-35) was administered as a measure of health-related quality of life by assessment of clinical, social, and care concerns, as well as treatment outcomes. The scale integrates concerns expressed by clinicians and health practitioners, as well as family and staff carers. It comprises four subscales: the 1st subscale – “concerns about seizures” (10 items), the 2nd subscale – “concerns about treatment” (nine items), the 3rd subscale – “concerns about caring” (eight items), and the 4th subscale – “concerns about social impact” (eight items). Every item is assessed according to a five-point scale: 0 = “never a concern”, 1 = “occasionally a concern”, 2 = “fairly often a concern”, 3 = “often a concern”, and 4 = “very often a concern”. The reliability, internal consistency, and validity of the GEOS-35 for use with clinical populations having epilepsy and mental retardation has been demonstrated by Espie et al 2001.¹ In our study, the GEOS-35 was completed by the principal caregivers of all included patients. We accepted the obtained total scores of the scale (corresponding to health-related QOL) as very low (106–140), low (71–105), medium (36–70), and high (1–35).

Data were processed using STATA Version 10 (Stata Corp., College Station, TX, U.S.A.) and SPSS (Statistical Package for the Social Sciences), version 14.0 (SPSS Inc., Chicago, IL, U.S.A.). Results for the quantitative variables are expressed as the mean \pm SE (standard error) and results for the qualitative variables are expressed as percentages. The indices of QOL were the principal outcomes. The associations of QOL with depression, anxiety, demographics, degree of cognitive impairment, stigmatisation, and clinical and social findings were tested by means of the χ^2 – Test and F – Test. Pearson's correlation coefficient (*r*) was used to determine correlations between the above mentioned characteristics. The complex influence of the significant clinical findings was determined by means of multivariate regression analysis. The level of significance was set at $P < 0.05$.

3. Results

Thirty-two (50%) of the participants in our study were men; the remaining 32 participants were women. Their mean age was 44.88 ± 1.84 years. The mean duration of epilepsy was 31.78 ± 1.60 years. The clinical findings, degree of cognitive impairment, depression, anxiety, stigma, and social characteristics of the participants with RE are shown in Table 1.

All study participants had been declared disabled, only two (3.13%) were occupied, and seven (10.94%) had retired on a pension.

The mean total score of the GEOS-35 was low (76 ± 2.34). The mean subscale scores were as follows: the 1st subscale (“concerns about seizures”) – 21.11 ± 0.86 (corresponding to

Download English Version:

<https://daneshyari.com/en/article/4318477>

Download Persian Version:

<https://daneshyari.com/article/4318477>

[Daneshyari.com](https://daneshyari.com)